Geode Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $780M | Buy |
|
|||||
|
2025
Q1 | $626M | Buy |
|
|||||
|
2024
Q4 | $518M | Buy |
|
|||||
|
2024
Q3 | $589M | Buy |
|
|||||
|
2024
Q2 | $505M | Buy |
|
|||||
|
2024
Q1 | $299M | Buy |
|
|||||
|
2023
Q4 | $368M | Buy |
|
|||||
|
2023
Q3 | $325M | Buy |
|
|||||
|
2023
Q2 | $342M | Buy |
|
|||||
|
2023
Q1 | $348M | Buy |
|
|||||
|
2022
Q4 | $401M | Buy |
|
|||||
|
2022
Q3 | $320M | Buy |
|
|||||
|
2022
Q2 | $229M | Buy |
|
|||||
|
2022
Q1 | $256M | Buy |
|
|||||
|
2021
Q4 | $255M | Buy |
|
|||||
|
2021
Q3 | $274M | Buy |
|
|||||
|
2021
Q2 | $245M | Buy |
|
|||||
|
2021
Q1 | $195M | Buy |
|
|||||
|
2020
Q4 | $170M | Buy |
|
|||||
|
2020
Q3 | $183M | Sell |
|
|||||
|
2020
Q2 | $190M | Sell |
|
|||||
|
2020
Q1 | $147M | Buy |
|
|||||
|
2019
Q4 | $143M | Buy |
|
|||||
|
2019
Q3 | $95.5M | Buy |
|
|||||
|
2019
Q2 | $76.9M | Buy |
|
|||||
|
2019
Q1 | $94M | Buy |
|
|||||
|
2018
Q4 | $66.7M | Buy |
|
|||||
|
2018
Q3 | $77M | Buy |
|
|||||
|
2018
Q2 | $79.4M | Buy |
|
|||||
|
2018
Q1 | $91.1M | Buy |
|
|||||
|
2017
Q4 | $94.9M | Buy |
|
|||||
|
2017
Q3 | $77.5M | Sell |
|
|||||
|
2017
Q2 | $52.8M | Buy |
|
|||||
|
2017
Q1 | $29.6M | Buy |
|
|||||
|
2016
Q4 | $20M | Buy |
|
|||||
|
2016
Q3 | $35.2M | Buy |
|
|||||
|
2016
Q2 | $27.7M | Buy |
|
|||||
|
2016
Q1 | $30.1K | Buy |
|
|||||
|
2015
Q4 | $42.2M | Buy |
|
|||||
|
2015
Q3 | $35.2M | Buy |
|
|||||
|
2015
Q2 | $52M | Buy |
|
|||||
|
2015
Q1 | $42.9M | Buy |
|
|||||
|
2014
Q4 | $33.8M | Buy |
|
|||||
|
2014
Q3 | $25.8M | Buy |
|
|||||
|
2014
Q2 | $20.5M | Buy |
|
|||||
|
2014
Q1 | $21.1M | Buy |
|
|||||
|
2013
Q4 | $18.3M | Buy |
|
|||||
|
2013
Q3 | $16.2M | Buy |
|
|||||
|
2013
Q2 | $6.81M | Buy |
|